Microbot Medical

Microbot Medical Equity Ratio

The Equity Ratio of Microbot Medical (MBOT) as of Nov 2, 2026 is 95.11 %. In the previous year, Equity Ratio was 58.53 % — a change of 62.49% (higher).

Equity Ratio

95.11 %

YoY

62.49%

Last updated:

Equity Ratio of Microbot Medical is 2025 95.11 % . Equity Ratio of Microbot Medical was 2024 58.53 % . It decreases by 62.49% higher compared to the previous year.

The Microbot Medical Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
21.84 USD
Jan 1, 2019
84.95 USD
Jan 1, 2020
92.50 USD
Jan 1, 2021
85.77 USD
Jan 1, 2022
76.43 USD
Jan 1, 2023
54.05 USD
Jan 1, 2024
58.53 USD
Jan 1, 2025
95.11 USD
The Microbot Medical Equity Ratio history
YEAREquity RatioYoY
95.11 %+62.49%
58.53 %+8.28%
54.05 %-29.28%
76.43 %-10.89%
85.77 %-7.28%
92.50 %+8.88%
84.95 %+289.00%
21.84 %-75.85%
90.42 %+79.56%
50.36 %-3,299.13%
-1.57 %-108.69%
18.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Microbot Medical Stock analysis

What does Microbot Medical do? Microbot Medical Inc. is a leading company in the development of microrobots for the medical field. The company was established in 2010 and is headquartered in Hingham, Massachusetts. Microbot Medical Inc. believes that the future of medicine lies in robotics and specializes in developing innovative solutions for complex surgical procedures and minimally invasive interventions. The company's business model is based on the development and commercialization of intelligent microrobots that will enable more precise and gentle surgical interventions. From the beginning, the company has focused on two main areas: the development of robot-assisted systems for neurosurgical procedures and the development of solutions for gastroenterology applications. In the field of neurosurgical procedures, Microbot Medical Inc. has developed the LIBERTY robot for market readiness. This robot is designed to assist surgeons during neurosurgical procedures that require increased precision and effectiveness. The robot aids the surgeon in navigating difficult-to-access areas of the brain and can help minimize the risk of tissue damage. Microbot Medical Inc. is also a leader in the development of robots in the gastroenterology field. The company has introduced the SELF-TESTER robot, which is capable of performing endoscopies in a more comfortable and painless manner. The SELF-TESTER is navigated through the digestive system and can help diagnose diseases such as cancer or inflammations in the gastrointestinal tract more effectively. Furthermore, Microbot Medical Inc. conducts research and development activities in the field of cardiovascular surgery. The company is working on a solution that allows doctors to implant aortic valves minimally invasively. The goal is to create an alternative to traditional open-heart surgery. The company has also signed a letter of intent with Cardiovascular Systems Inc. to jointly bring a new product to market that has the potential to further accelerate the minimally invasive aortic valve implantation procedure. In recent years, Microbot Medical Inc. has received several awards and recognitions, including an award from Frost & Sullivan in the category of "New Product Innovation." The company has also formed important partnerships with other leaders in the medical technology field to support the development and commercialization of its products. In conclusion, Microbot Medical Inc. is one of the leading providers of intelligent robots for the medical field and will play an important role in the development of advanced technologies that contribute to making surgical interventions more effective and safer in the coming years. The company is committed to driving innovations in medical technology and has already made a name for itself by successfully developing products in various areas. Microbot Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Microbot Medical stock

Equity Ratio of Microbot Medical is 95.11 % in 2025.

Equity Ratio of Microbot Medical changed from 58.53 % to 95.11 %, representing a 62.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Microbot Medical since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Microbot Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Microbot Medical

All Key Metrics — Microbot Medical